Novozymes, a developer and manufacturer of enzymes for such uses as biofuels, will buy the enzyme-related assets of Biocon Limited, an Indian company, the firm said Wednesday.
Novozymes’ U.S. headquarters is located in Franklinton. It is based in Denmark.
Biocon will sell its enzyme-related business operation to Novozymes for $115 million. The price includes $13 million in service fees and lease payments to be made over 10 years,
Biocon, a biotechnology company, is located in Bangalore, where Novozymes is setting up a research and development facility.
